Professional Documents
Culture Documents
Indiatos
BUSINESS NEWS
PLANT WATCH
enzvm ft bu"d add-ilonal blologlos tarullachuln plantInlelgum
January22 2011 - Genzyme Corp. (Cambridge, Mass.; www.genzyme.com) plans to build an additional manufacturing plant in Geel, Belgium, to support the longterm growth of Alglucosidase alfa, known as Lumizyme Inthe U.S. and as Myozyme inthe rest of the world, for Pompe disease,The new f250-million plant will include 8,000 Lof production capacity,a complete purification Installation, and ample room for additional future capacity exponsions.Commercial approvals for the new site are expected to start In late 2014. gen peroxide production plant by Evodk and a propylene oxide facility by GACLThe aim isto produce propylene oxide using the environmentally friendly HPPO (hydrogen peroxide to propylene oxide) process developed jointly by Evonik and Uhde GmbH (Dortmund, Germany; www.uhde.eu).The project Is contingent upon the approval of the executive board and supervisory board of Evonlk Industries AG. Sememns to supply I&C sysem and turbines for olorwihenall power January 11, 2011 - Siemens Energy (Orlando, Flo.; www.siemens.com/energy) will supply an instrumentation &controls (Q&C) system and two steam-turbine generators for the Ivanpah solar-thermal power plant located in California's Mojave desert.The purchaser isBrightSource Energy Inc. (Oakland, Calff.).The three units for the tvanpah project will have a combined installed capacity of approximately 400 megawatts (MW).The start of commercial operation of the Ivanpah Units 2 and 3 Isscheduled for 2013.The plant's capacity will be sufficient to supply approximately 140.000 households with clean power and isexpected to reduce annual CO 2 emissions by more than 400,000 tons.
MIEEH Ann AroUlln6UIOU
SHC-4aialln acquiresoefghweeuing
firm In Columnbi January,12,2011 -SNC-Lavaln inc. (Montreal; Canada;owww,sncoiIn.oom) has acquied kansuca Proyectosde kgeneria SA.aneng1neeong firm based InBogota.CAomblo. Lantmen xmks it first
aoquiuillonlIn Aigentilna
January 12, 2011 - Lanxess AG's (Leverkusen, Germany; www.anress.com) wholly owned subsidlary Rhein Chemie (Mannhelm, Germany), has acquired Argentinabased Darmex S.A. (Buenos Aires) - a loadIng manufacturer of release agents and curing bladders for the tire Industry. Both parties have agreed not to disclose the purchase prfce.The transaction will close with immediate effect and does not require prior approval by any authority
Chemle AG. As part of the planned tronsaction, Clarlant has come to agreements
with the majority shareholder One Equity Partners (50.4%) and the family shareholders the licensing and IPCenter of MaimTecnimont S.p.A. (www.moiretecnlmont.It) has
(approximately 46%). Clarlont will acquire slightly above 95%of the outstanding shares. The total value of the transaction isf2,0 billion (CHF 2.5 billion). After all necessary regulatory approvals, including anti-trust, are obtained. Clarlant expects the transaction will be completed in the first half of 2011.
Intellectual propery Including applicable patents and know-how Inthe field of stymne catalysts, as well as CRl/Crlterlon's styrene catalysts Inventory.There were no plant assets associated with the deal. a
DOothy^Lowwk
A 0009-2460) Ispt&Ashled monft*,y with on additional Msue In Octoker. by Acorns hiellsgenoe, LLC.Choke Cherry Road, CherrcA,o &ngknv&*n copyrIght @2011 (WSN 2nd loor. Rockv,0e, MD. 20850. Chemical EngIneerng eSoutie. Editorial. Advertising and PublicatIon Ofees: 110 WV0arn Steet. 11th Floor. Now York NY 10038W Phone: 212-621-4674. Fax: 212.621-4694. subscription rates: $120,97 U.S. U.S. and posseWons. $146.97 Canada, and $249 Inhlatlanl. $20.00 Bock Issue & SWVW oopy sos PerkIodIls postage paid at Rockville MD and adoItional mading afficee. Poetmoster: Send address changes to Chermica Engineeft,g Fuftnerf MNfgerxw PO. Smr 3688. Northbrook IL 60066-3588. Phone: 847-664-9290. Fax: 847464-9453, eraIl: cilenheMoesfthe.com. Change of address, two to eight wee notice requested. For nlrrnalon "regarngarticle reprints, please contact Woghfs Medic. 1-877-662-5295, .comtne. Contents may not be reproduced inany*fom wfthout wi perfrissIon. PubltolNs MMO Produot late iAgrement Ne. PM4,03731. Retunmd vae Ctadin Addmwm#w RO.SM* 151, W lw*mKW 7 to: O N9A70%
FO NA ECONOMIC INDICATORS, SEENEXT PAGE CHEMICL ENGINEERING WWW,CHE.COM MAC 2011 W
IU1N1-'=VO1:0L119M3.S
I Ec
.. . .s
200911111111111
20110migo
2011111111111
PREVIOUS
Dec.'10 Nov.'10 Dec.'10 Dec.'10 Dec.'10 Dec.'10 Dec.'10 91.5 1,893.4 74.1 282.8 92.3 154.6 125.4 Nov.'1 0 Oct.'l 0 Nov.10 Nov.'10 Nov.10 Nov.'10 Nov.'10 90.2 1,836.7 72.9 276.0 91.6 154.9 123.3
YE4R AGO Jan.'10 D9e'09 Jan.'10 Jan.'10 Jan.'10 Jan.'10 Jan,110 = 87.7 = 1,765.7 70.3 = = 261.7 = 87.8 = 150.4 = 117.8
11
.. I-I.II
. . . . . . . . . . I
I 19000
i L II
L ;I
I
II
I'
70
I I ,II I I I 11-1 I
JF.MAMJ.JA80ND
CURRENT TRENDS apital equipment prices (as reflected in the CE Plant Cost Index) increased from November to December. Meanwhile, Global Insight's CPI operating rate and output index were relatively flat. According to the American Chemistry Council's (Arlington, Va.; www.americanchemistry, corn) most-recent weekly economic report at CE press time, inflation in the U.S. at the consumer level "remains tame," but inflation pressures are building in China, Europe and many emerging markets. Also, industrial production gains in overseas markets seem to be moderating, the report adds. Visit www.che.com/pci for historical data and more on capital cost trends and methodology. N
COPYRIGHT INFORMATION
Author: Lozowski, Dorothy Title: Economic indicators Source: Chem Eng (U S) 118 no3 Mr 2011 p. 63-4 ISSN: 0009-2460 Publisher: Access Intelligence, LLC 4 Choke Cherry Road, 2nd Floor, Rockville, MD 20850
The magazine publisher is the copyright holder of this article and it is reproduced with permission. Further reproduction of this article in violation of the copyright is prohibited. To contact the publisher: http://www.che.com/
This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sublicensing, systematic supply or distribution in any form to anyone is expressly forbidden. The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.